Sarcopenia disease in Iran: an overview
- 3 Downloads
Sarcopenia is a geriatric disease with adverse clinical outcomes, high rate of mortality and a major challenge to healthy elderly. This study aimed to undertake a survey to identify gaps and highlight strengths in sarcopenia research in order to progress research in this area for the next years in Iran.
This study included all studies published from the beginning until the first of 2019 in national and international journals by Iranian authors conducted in the field of sarcopenia. The databases including MEDLINE (via PubMed), Web of Science and SCOPUS were used as the sources of information. All relevant available academic studies, including review articles, original articles, case reports, conference abstracts, and letters were included in the analysis.
A total of 48 articles obtained and then categorized into six groups. These groups were; about Pathophysiology, Epidemiology of sarcopenia, Screening of sarcopenia, Nutrition, Physical activity and Association of Sarcopenia and Other Diseases that briefly findings of each study had been described. These findings showed that the prevalence of sarcopenia was 16.5% to 32.5%, using different definitions. A study developed and validated a screening model for identifying people with sarcopenia. Lifestyle changes such as diet can be appropriate strategies for the prevention of sarcopenia and also, physical activity is considered to be one of the few effective strategies to improve sarcopenia and prevent its outcomes, especially if in combination with appropriate nutritional supplementation. Sarcopenia is associated with adverse outcomes and other serious areas such as metabolic disorders, cancers, cardiovascular diseases, nephrology, gastroenterology, psychiatry, other geriatric diseases (such as osteoporosis, etc) and death. Some studies about these areas have been done in Iran.
By this study, we found that studies on sarcopenia, the gaps of sarcopenia research in Iran, and highlighted the research priorities for future works. The outcome of the present research is to ultimately improve the health, quality of life and well-being of sarcopenic people.
KeywordsSarcopenia Research Iran
Compliance with ethical standards
Conflict of interest
The authors declared that they have no conflict of interest.
- 4.Fielding RA, Vellas B, Evans WJ, Bhasin S, Morley JE, Newman AB, et al. Sarcopenia: an undiagnosed condition in older adults. Current consensus definition: prevalence, etiology, and consequences. International working group on sarcopenia. J Am Med Dir Assoc. 2011;12(4):249–56.CrossRefPubMedPubMedCentralGoogle Scholar
- 5.Shafiee G, Ostovar A, Heshmat R, Keshtkar AA, Sharifi F, Shadman Z, et al. Appendicular skeletal muscle mass reference values and the peak muscle mass to identify sarcopenia among Iranian healthy population. Int J Prev Med 2018;9.Google Scholar
- 10.Shafiee G, Keshtkar A, Soltani A, Ahadi Z, Larijani B, Heshmat R. Prevalence of sarcopenia in the world: a systematic review and meta-analysis of general population studies. J Diabetes Metab Disord 2017;16.Google Scholar
- 12.Bakhtiari N, Moslemee-Jalalvand E, Kazemi J. Ursolic acid: a versatile triterpenoid compound in regulating the aging. Physiology and Pharmacology. 2017;21(1):15–24.Google Scholar
- 13.Bakhtiari N. Isolation and optimization of mice skeletal muscle satellite cells using preplating method and culture media substitution. Physiology and Pharmacology. 2016;20(1):63–73.Google Scholar
- 14.Shafiee G, Heshmat R, Larijani B. Circulating cell-free nucleic acids as potential biomarkers for sarcopenia: a step toward personalized medicine. J Diabetes Metab Disord 2017;16.Google Scholar
- 18.Abiri B, Vafa M. Nutrition and sarcopenia: a review of the evidence of nutritional influences. Crit Rev Food Sci Nutr 2017:1–11.Google Scholar
- 23.Mafi F, Biglari S, Afousi AG, Gaeini AA. Epicatechin supplementation and resistance training-induced improvement of muscle strength and circulatory levels of plasma Follistatin and Myostatin in Sarcopenic older adults. J Aging Phys Act 2018:1–27.Google Scholar
- 25.Heshmat R, Shafiee G, Ostovar A, Sharifi F, Nabipour I, Larjani B. Socioeconomic inequality of sarcopenia in iran: bushehr elderly health program. Osteoporos Int. 2018;29:S332.Google Scholar
- 26.Dassie GA, Motlagh AD, Chamari M, Mohammadreza E. Prevalence of food insecurity and its association with muscle mass, hand grip strength and gait speed among elderly in tehran. Int J Pharm Sci Res. 2016;7(7):2889–95.Google Scholar
- 27.Larijani B, Shafiee G, Shadman Z, Ostovar A, Heshmat R, Taheri E, et al. Association between nutritional status and sarcopenia in a community dwelling older population: The Bushehr Elderly Health (BEH) Program. J Bone Miner Res. 2018;33:439.Google Scholar
- 28.Vafa MR. Vitamin D and Sarcopenia. Adv Obes, Weight Manag Contrl. 2017;6(3):00155.Google Scholar
- 29.Ziaaldini MM, Marzetti E, Picca A, Murlasits Z. Biochemical pathways of sarcopenia and their modulation by physical exercise: a narrative review. Front Med 2017;4.Google Scholar
- 31.Nourshahi M, Hedayati M, Gholamali M. Relationship between plasma myostatin with muscular volume and muscular maximal strength and it's response to acute resistance exercise in the elderly. Koomesh. 2013;15(1):102–9.Google Scholar
- 34.Mansouri MRM, Haghighi AH, Askari R. Exercises of lumbar stabilizer muscles, resistance training, and soy food consumption: a comparative study between old and young women. Salmand. 2017;12(1):44–55.Google Scholar
- 38.Shafiee G, Heshmat R, Ostovar A, Sharifi F, Razi F, Nabipour I, et al. Association of sarcopenia and its parameters with type 2 diabetes: the bushehr elderly health program. Osteoporos Int. 2018;29:S328–S9.Google Scholar
- 39.Heshmat R, Shafiee G, Ostovar A, Sharifi F, Razi F, Nabipour I, et al. Association between metabolic syndrome and muscle health, quality and quantity of bone: the bushehr elderly health program. Osteoporos Int. 2018;29:S333.Google Scholar
- 41.Sharifi F, Shafiee G, Heshmat R, Nabipour I, Larijani B, Arzaghi SM, et al. Association of cognitive impairment and sacopenia in older adults: bushehr elderly health project. Osteoporos Int. 2018;29:S483.Google Scholar
- 42.Larijani B, Shafiee G, Ostovar A, Heshmat R, Sharifi F, Nabipour I. Association of osteosarcopenia and cognitive impairment in a community dwelling older population: The Bushehr Elderly Health (BEH) program. J Bone Miner Res. 2018;33:313.Google Scholar
- 44.Aghili R, Malek M, Valojerdi AE, Banazadeh Z, Najafi L, Khamseh ME. Body composition in adults with newly diagnosed type 2 diabetes: Effects of metformin. J Diabetes Metab Disord. 2014;13(1).Google Scholar
- 47.Heshmat R, Shafiee G, Ostovar A, Sharifi F, Razi F, Nabipour I, et al. Association of OSTEOSARCOPENIA with CARDIOMETABOLIC risk factors in older people: BUSHEHR elderly health program. Osteoporos Int. 2018;29:S332–S3.Google Scholar
- 48.Shafiee G, Heshmat R, Ostovar A, Sharifi F, Nabipour I, Larijani B. Association of sarcopenia components and bone parameters with risk of falling in older people: the bushehr elderly health program. Osteoporos Int. 2018;29:S328.Google Scholar
- 50.Penson PE, Mancini GBJ, Toth PP, Martin SS, Watts GF, Sahebkar A, et al. Introducing the ‘Drucebo’ effect in statin therapy: a systematic review of studies comparing reported rates of statin-associated muscle symptoms, under blinded and open-label conditions. J Cachexia Sarcopenia Muscle. 2018;9(6):1023–33.PubMedPubMedCentralCrossRefGoogle Scholar